Evidence of efficacy of OCA for PBC patients

Evidence of efficacy of OCA for PBC patients

A study published in the Gastroenterology (September 2022) showed that people receiving OCA for primary biliary cholangitis (PBC) in a clinical trial setting had greater transplant-free survival to patients with PBC selected from “real-world” patient registries who did not receive OCA. Key findings include: patients treated with OCA had an approximately 70 percent lower relative risk of death or liver transplant than the control patients at any time during follow-up.  Read more now.